The average life expectancy after an ALS diagnosis is three to five years. But that number doesn’t tell the whole story. About 20% of people with ALS live five years or more, roughly 10% live beyond ten years, and around 5% survive twenty years or longer. Where someone falls on that spectrum depends on several factors, including where symptoms first appear, age at diagnosis, and the type of breathing support they use.
Where Symptoms Start Matters
ALS generally begins in one of two ways. In limb-onset ALS, weakness first appears in the arms or legs. In bulbar-onset ALS, it starts in the muscles controlling speech and swallowing. About two-thirds of cases are limb-onset, and this distinction has a real effect on prognosis.
People with bulbar-onset ALS tend to have shorter survival for a few reasons. They’re more likely to be older when symptoms begin, they develop breathing problems sooner, and they face greater difficulty using breathing support devices effectively. Once respiratory involvement develops, the monthly mortality risk for bulbar-onset patients is roughly double that of limb-onset patients, even when both groups are using the same type of breathing assistance.
How Breathing Support Changes the Timeline
Respiratory failure is the primary cause of death in ALS. The diaphragm and other breathing muscles gradually weaken, eventually making it impossible to breathe without assistance. This is where treatment decisions have the biggest impact on survival.
Non-invasive ventilation (a mask-based breathing device, often used at night) substantially extends life when used correctly. Patients who use non-invasive ventilation survive a median of 21 to 48 months from symptom onset, compared to just 8 to 15 months for those who don’t use it at all. The key word is “correctly.” Patients who wear the device for more than four consecutive hours at night survive significantly longer than those who use it for shorter periods (22 months versus 15 months in one comparison). When the device isn’t properly calibrated to clear airway obstructions, it can cut survival by half compared to effective use.
Some people choose invasive ventilation through a tracheostomy, a surgical opening in the windpipe connected to a mechanical ventilator. This option dramatically extends survival. In a Norwegian national study tracking patients over 12 years, the median survival with tracheostomy was about 75 months (over six years), compared to roughly 15 months with non-invasive ventilation alone. However, tracheostomy ventilation requires 24-hour caregiving, and many people with ALS decide against it for quality-of-life reasons.
Age and Genetics
Younger age at diagnosis is one of the strongest predictors of longer survival. People diagnosed before age 40 are far more represented among long-term survivors than those diagnosed later in life. Stephen Hawking, perhaps the most famous example, was diagnosed at 21 and lived more than 50 years with the disease, though his case was exceptionally rare.
About 5 to 10% of ALS cases are familial, meaning they’re linked to inherited genetic mutations. The most common is the C9orf72 gene expansion, which carries a less favorable prognosis than typical sporadic ALS, particularly when combined with older age at onset or bulbar symptoms. Another mutation, in the SOD1 gene, has recently become treatable with a targeted therapy that slows the rate of functional decline, though long-term survival data for that treatment are still being collected.
What Medications Can Do
The first drug approved for ALS extends life by a modest two to three months on average, translating to about a 9% increase in one-year survival. That may sound small, but in a disease with no cure, even incremental gains matter, and the benefit may be larger when treatment starts early.
Beyond medication, the biggest survival gains come from multidisciplinary care: coordinated teams managing nutrition (since swallowing difficulties can lead to dangerous weight loss), breathing support, physical therapy, and communication tools. People treated at specialized ALS clinics consistently survive longer than those who aren’t, likely because problems like inadequate breathing support or malnutrition get caught and addressed sooner.
Why Averages Can Be Misleading
The “three to five years” figure is an average that blends very different trajectories. Some people decline rapidly within a year of diagnosis, while others remain functional for a decade or more. The speed of progression in the first few months after symptoms appear is itself a strong clue. People whose function declines slowly in the early stages tend to continue on that slower trajectory.
The causes of death in ALS are primarily respiratory failure, followed by cardiovascular complications and cardiac arrest. Because respiratory failure is so central, the timing and quality of breathing support are the single most controllable factor in how long someone lives with the disease. Early referral to a pulmonologist and proactive use of ventilation can meaningfully shift the timeline.